帕博利珠单抗治疗晚期软组织与骨肉瘤的II期SARC028研究
SARC028是一项多中心、两队列、单臂、开放标签II期试验,评估帕博利珠单抗200 mg每3周静脉给药在晚期软组织肉瘤或骨肉瘤患者中的安全性与活性。软组织肉瘤队列40例可评估患者中7例(18%)客观缓解,骨肉瘤队列40例中2例(5%)客观缓解;两队列主要终点均未达到,但未分化多形性肉瘤和去分化脂肪肉瘤显示令人鼓舞的活性。
要点
- 软组织肉瘤队列客观缓解7/40(18%),其中未分化多形性肉瘤4/10(40%)。
- 骨肉瘤队列客观缓解2/40(5%),平滑肌肉瘤和尤文肉瘤均无客观缓解。
- 两队列主要终点均未达到,但未分化多形性肉瘤和去分化脂肪肉瘤显示令人鼓舞的活性。
核心结论
- 两队列主要终点总体客观缓解均未达到,但帕博利珠单抗在未分化多形性肉瘤或去分化脂肪肉瘤患者中显示出令人鼓舞的活性。
- 正在入组这些亚型的扩展队列,以确认和表征帕博利珠单抗的活性。
研究设计与样本
- 多中心、两队列、单臂、开放标签II期研究,自美国12家学术中心入组患者。
- 软组织肉瘤患者须≥18岁,骨肉瘤患者可≥12岁;须有转移性或不可手术切除的局部晚期肉瘤组织学证据,既往全身抗癌治疗≤3线。
- 所有患者接受帕博利珠单抗200 mg静脉给药每3周一次;主要终点为研究者评估的客观缓解。
- 共入组86例患者,84例接受帕博利珠单抗(每队列42例),80例可评估缓解(每队列40例)。
主要发现
- 软组织肉瘤队列40例中7例(18%)客观缓解,包括未分化多形性肉瘤4/10(40%)、脂肪肉瘤2/10(20%)、滑膜肉瘤1/10(10%)。
- 软组织肉瘤队列中平滑肌肉瘤10例均无客观缓解。
- 骨肉瘤队列40例中2例(5%)客观缓解,包括骨肉瘤1/22(5%)和软骨肉瘤1/5(20%)。
- 骨肉瘤队列中尤文肉瘤13例均无客观缓解。
- 骨肉瘤组最常见≥3级不良事件为贫血6例(14%)、淋巴细胞计数降低5例(12%)、活化部分凝血活酶时间延长4例(10%)、血小板计数降低3例(7%);软组织肉瘤组贫血、淋巴细胞计数降低和活化部分凝血活酶时间延长各3例(7%)。
关键数值与推荐
- 软组织肉瘤队列客观缓解7/40(18%),骨肉瘤队列2/40(5%)。
- 未分化多形性肉瘤客观缓解4/10(40%),脂肪肉瘤2/10(20%),滑膜肉瘤1/10(10%),平滑肌肉瘤0/10。
- 骨肉瘤客观缓解1/22(5%),软骨肉瘤1/5(20%),尤文肉瘤0/13。
- 帕博利珠单抗给药方案为200 mg静脉给药每3周一次。
临床怎么用
- 帕博利珠单抗200 mg每3周一次用于晚期软组织肉瘤或骨肉瘤患者,两队列主要终点总体客观缓解均未达到。
- 未分化多形性肉瘤或去分化脂肪肉瘤患者中观察到令人鼓舞的活性,相关亚型扩展队列正在入组以确认和表征活性。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with advanced sarcomas have a poor prognosis and few treatment options that improve overall survival. Chemotherapy and targeted therapies offer short-lived disease control. We assessed pembrolizumab, an anti-PD-1 antibody, for safety and activity in patients with advanced soft-tissue sarcoma or bone sarcoma. METHODS: In this two-cohort, single-arm, open-label, phase 2 study, we enrolled patients with soft-tissue sarcoma or bone sarcoma from 12 academic centres in the USA that were members of the Sarcoma Alliance for Research through Collaboration (SARC). Patients with soft-tissue sarcoma had to be aged 18 years or older to enrol; patients with bone sarcoma could enrol if they were aged 12 years or older. Patients had histological evidence of metastatic or surgically unresectable locally advanced sarcoma, had received up to three previous lines of systemic anticancer therapy, had at least one measurable lesion according to the Response Evaluation Criteria In Solid Tumors version 1.1, and had at least one lesion accessible for biopsy. All patients were treated with 200 mg intravenous pembrolizumab every 3 weeks. The primary endpoint was investigator-assessed objective response. Patients who received at least one dose of pembrolizumab were included in the safety analysis and patients who progressed or reached at least one scan assessment were included in the activity analysis. Accrual is ongoing in some disease cohorts. This trial is registered with ClinicalTrials.gov, number NCT02301039. FINDINGS: Between March 13, 2015, and Feb 18, 2016, we enrolled 86 patients, 84 of whom received pembrolizumab (42 in each disease cohort) and 80 of whom were evaluable for response (40 in each disease cohort). Median follow-up was 17·8 months (IQR 12·3-19·3). Seven (18%) of 40 patients with soft-tissue sarcoma had an objective response, including four (40%) of ten patients with undifferentiated pleomorphic sarcoma, two (20%) of ten patients with liposarcoma, and one (10%) of ten patients with synovial sarcoma. No patients with leiomyosarcoma (n=10) had an objective response. Two (5%) of 40 patients with bone sarcoma had an objective response, including one (5%) of 22 patients with osteosarcoma and one (20%) of five patients with chondrosarcoma. None of the 13 patients with Ewing's sarcoma had an objective response. The most frequent grade 3 or worse adverse events were anaemia (six [14%]), decreased lymphocyte count (five [12%]), prolonged activated partial thromboplastin time (four [10%]), and decreased platelet count (three [7%]) in the bone sarcoma group, and anaemia, decreased lymphocyte count, and prolonged activated partial thromboplastin time in the soft-tissue sarcoma group (three [7%] each). Nine (11%) patients (five [12%] in the bone sarcoma group and four [10%] in the soft-tissue sarcoma group) had treatment-emergent serious adverse events (SAEs), five of whom had immune-related SAEs, including two with adrenal insufficiency, two with pneumonitis, and one with nephritis. INTERPRETATION: The primary endpoint of overall response was not met for either cohort. However, pembrolizumab showed encouraging activity in patients with undifferentiated pleomorphic sarcoma or dedifferentiated liposarcoma. Enrolment to expanded cohorts of those subtypes is ongoing to confirm and characterise the activity of pembrolizumab. FUNDING: Merck, SARC, Sarcoma Foundation of America, QuadW Foundation, Pittsburgh Cure Sarcoma, and Ewan McGregor.
引用
- Tawbi HA, Burgess M, Bolejack V, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017. PMID: 28988646. doi:10.1016/S1470-2045(17)30624-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。